Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
65.59
-1.92 (-2.84%)
After Hours: 65.61 +0.02 (0.03%)
Feb 5, 4:58PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 63.70 - 68.01
52 week 61.09 - 140.00
Open 67.22
Vol / Avg. 1.33M/927,060.00
Mkt cap 5.81B
P/E     -
Div/yield     -
EPS -2.65
Shares 84.74M
Beta 2.54
Inst. own 78%
Apr 29, 2016
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 8:30AM EDT - Add to calendar
Feb 11, 2016
Q4 2015 Alnylam Pharmaceuticals Inc Earnings Call - 4:30PM EST - Add to calendar
Feb 11, 2016
Q4 2015 Alnylam Pharmaceuticals Inc Earnings Release - 4:00PM EST - Add to calendar
Feb 10, 2016
Alnylam Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference - 1:25PM EST - Add to calendar
Feb 9, 2016
Alnylam Pharmaceuticals Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference - 3:00PM EST - Add to calendar
Jan 11, 2016
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference (Q&A)
Jan 11, 2016
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference
Jan 5, 2016
Alnylam Pharmaceuticals Inc at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top Conference
Dec 10, 2015
Alnylam Pharmaceuticals Inc R&D Day
Dec 9, 2015
Alnylam Pharmaceuticals Inc at Oppenheimer Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -1214.30% -712.79%
Operating margin -1238.62% -800.97%
EBITD margin - -777.39%
Return on average assets -20.76% -48.05%
Return on average equity -22.56% -59.74%
Employees 256 -
CDP Score - -

Address

300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Company’s pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.

Officers and directors

Michael W. Bonney Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Barry E. Greene President, Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D., Ph.D. Executive Vice President - Research and Development ,Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Laurie B. Keating Senior Vice President - General Counsel, Secretary
Age: 60
Bio & Compensation  - Reuters
David-Alexandre Gros Senior Vice President, Chief Business Officer
Age: 43
Bio & Compensation  - Reuters
Michael P. Mason Vice President - Finance, Treasurer
Age: 40
Bio & Compensation  - Reuters
John K. Clarke Director
Age: 61
Bio & Compensation  - Reuters
David E. I. Pyott Director
Age: 62
Bio & Compensation  - Reuters
Amy W. Schulman Director
Age: 54
Bio & Compensation  - Reuters